|
See related Peg-Intron powd for inj information |
|
|
|
Manufacturer |
MSD |
|
Distributor |
Zuellig |
|
Contents |
Peginterferon α-2b |
|
Indications |
Treatment of Chronic Hepatitis B & C in adult ≥18 yr & have compensated liver disease.
Click to view Peg-Intron detailed prescribing infomation |
|
Dosage |
Treatment of Chronic Hepatitis C Monotherapy 0.5 or 1 mcg/kg once wkly SC for at least 6 mth. Combination therapy 1.5 mcg/kg/wk SC w/ ribavirin cap based on patient's body wt: Patient >105 kg 1,400 mg/day ribavirin, 81-105 kg 1,200 mg/day ribavirin, 65-80 kg 1,000 mg/day ribavirin <65 kg 800 mg/day ribavirin. Taken in 2 divided doses in the morning & evening. In patient (Genotype I) exhibiting virological response at wk 12, treatment should be continued for another 9-mth period. In the subset of patients w/ genotype 1 infection & low viral load (<2,000,000 copies/mL) who became HCV-RNA negative at treatment wk 4 & remain HCV-RNA negative at wk 24, the treatment could either be stopped after this 24 wk treatment course or pursued for an additional 24 wk. Genotypes 2 or 3: Treated for 24 wk. Genotype 4: Same as genotype 1. HIV/HCV co-infection duration of treatment: 48 wk, regardless of genotype. Treatment of Chronic Hepatitis B 1 or 1.5 mcg/kg once wkly SC for 24 wk in HBe positive & for 48 wk in HBe negative. Dose should be selected based on the anticipated efficacy & safety. Patients w/ hard to treat genotypes C & D may benefit from the higher dose & longer duration.
Click to view Peg-Intron detailed prescribing infomation |
|
Overdosage |
View Peg-Intron overdosage for action to be taken in the event of an overdose. |
|
Contraindications |
Hypersensitivity to interferon, autoimmune hepatitis or a history of autoimmune disease, preexisting severe psychiatric condition or a history of severe psychiatric disorder, preexisting thyroid abnormalities that cannot be corrected by medication, decompensated liver disease. Pregnancy.
Click to view Peg-Intron detailed prescribing infomation |
|
Special Precautions |
Renal impairment. Patient who develop fatigue, somnolence or confusion during treatment are cautioned to avoid driving or operating machinery. History of CHF, MI &/or previous or current arrhythmic disorders. Any patient complaining of loss of visual acuity or visual field must have an eye exam. Monitor patient who develop psychiatric or CNS problems, including clinical depression, preexisting psoriatic disease. Lactation.
Click to view Peg-Intron detailed prescribing infomation |
|
Adverse Drug Reactions |
Headache, myalgia. Very commonly, inflammation at inj site, fatigue, rigors, fever, depression, arthralgia, nausea, alopecia, musculoskeletal pain, irritability, flu-like symptoms, insomnia, diarrhea, abdominal pain, asthenia, pharyngitis, wt decrease, anorexia, anxiety, impaired concentration, dizziness. Commonly, pruritus, dry skin, malaise, increase sweating, right upper quadrant pain, neutropenia, rash, vomiting, dry mouth, emotional lability, nervousness, dyspnea, viral infection, somnolence, thyroid disorder, chest pain, dyspepsia, flushing, paresthesia, coughing, agitation, sinusitis, hypertonia, hyperesthesia, blurred vision, confusion, flatulence, decreased libido, erythema, eye pain, apathy, hypoesthesia, loose stool, conjunctivitis, nasal congestion, constipation, vertigo, menorrhagia, menstrual disorder.
View ADR Monitoring Form |
|
Drug Interactions |
[Click for Peg-Intron detailed prescribing infomation]
View more drug interactions with Peg-Intron |
|
Pregnancy Category (US FDA) |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
Caution For Usage |
For caution against possible variation of physical aspect of medicine... click to view Peg-Intron detailed prescribing infomation |
|
Storage |
View Peg-Intron storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Peg-Intron description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Peg-Intron mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
